Akira Abe from 1125 Nielsen Ct APT 4, Ann Arbor, MI 48105, age 71, Phone: 7344767691

view source

Author
Akira Abe

ISBN #
4759905804

view source

Author
Akira Abe

ISBN #
4828820930

view source

Author
Akira Abe

ISBN #
4828820949

Methods And Compositions For Using Alveolar Macrophage Phospholipase A2
view source
US Patent:

7319015, Jan 15, 2008
Filed:

Apr 28, 2005
Appl. No.:

11/117161
Inventors:

James A. Shayman - Ann Arbor MI, US
Akira Abe - Ann Arbor MI, US
Miki Hiraoka - Ann Arbor MI, US
Assignee:

The Regents of The University of Michigan - Ann Arbor MI
International Classification:

C12Q 1/42
US Classification:

435 21, 435198, 424 946
Abstract:

The present invention is directed to methods and compositions for improving pulmonary surfactant catabolism. More specifically, the specification describes methods and compositions for making and using a lysosomal phospholipase A2 in methods for the diagnosis, and treatment of disorders of phospholipid catabolism such as pulmonary alveolar proteinosis.

Methods And Compositions For Using Aleveolar Macrophage Phospholipase A2
view source
US Patent:

7582442, Sep 1, 2009
Filed:

Mar 15, 2005
Appl. No.:

11/080257
Inventors:

James A. Shayman - Ann Arbor MI, US
Akira Abe - Ann Arbor MI, US
Miki Hiraoka - Ann Arbor MI, US
Assignee:

The Regents of the University of Michigan - Ann Arbor MI
International Classification:

C12Q 1/42
US Classification:

435 21, 435198, 424 946
Abstract:

The present invention is directed to methods and compositions for improving pulmonary surfactant catabolism. More specifically, the specification describes methods and compositions for making and using a lysosomal phospholipase A2 in methods for the diagnosis, and treatment of disorders of phospholipid catabolism such as pulmonary alveolar proteinosis.

Lysosomal Phospholipase A2 (Lpla2) Activity As A Diagnostic And Therapeutic Target For Identifying And Treating Systemic Lupus Erythematosis
view source
US Patent:

8052970, Nov 8, 2011
Filed:

Jun 30, 2009
Appl. No.:

12/495209
Inventors:

James A. Shayman - Ann Arbor MI, US
Akira Abe - Ann Arbor MI, US
Robert Kelly - Trenton MI, US
Jessica Kollmeyer - Ypsilanti MI, US
Ye Lu - Ann Arbor MI, US
Assignee:

The Regents of the University of Michigan - Ann Arbor MI
International Classification:

A61K 38/46
US Classification:

424 946, 424 94, 435375, 435 19
Abstract:

The present invention is directed to methods for diagnosis and treatment of systemic lupus erythematosus and drug-induced systemic lupus erythematosus. More specifically, the specification describes methods using a lysosomal phospholipase A2 in methods for the diagnosis and treatment of autoimmune disorders such as systemic lupus erythematosus and drug-induced systemic lupus erythematosus.

Lysosomal Phospholipase A2 (Lpla2) Activity As A Diagnostic And Therapeutic Target For Identifying And Treating Systemic Lupus Erythematosis
view source
US Patent:

20120121571, May 17, 2012
Filed:

Oct 13, 2011
Appl. No.:

13/272949
Inventors:

James A. Shayman - Ann Arbor MI, US
Akira Abe - Ann Arbor MI, US
Robert Kelly - Trenton MI, US
Jessica Kollmeyer - Ypsilanti MI, US
Ye Lu - Ann Arbor MI, US
Assignee:

THE REGENTS OF THE UNIVERSITY OF MICHIGAN - Ann Arbor MI
International Classification:

A61K 38/46
A61P 29/00
US Classification:

424 946
Abstract:

The present invention is directed to methods for diagnosis and treatment of systemic lupus erythematosus and drug-induced systemic lupus erythematosus. More specifically, the specification describes methods using a lysosomal phospholipase A2 in methods for the diagnosis and treatment of autoimmune disorders such as systemic lupus erythematosus and drug-induced systemic lupus erythematosus.

Glucosylceramide Synthase Inhibitors And Therapeutic Methods Using The Same
view source
US Patent:

20130095089, Apr 18, 2013
Filed:

Oct 15, 2012
Appl. No.:

13/652016
Inventors:

The Regents of The University of Michigan - Ann Arbor MI, US
Akira Abe - Ann Arbor MI, US
Liming Shu - Ann Arbor MI, US
Michael William Wilson - Ann Arbor MI, US
Richard F. Keep - Ann Arbor MI, US
James A. Shayman - Ann Arbor MI, US
Assignee:

The Regents of The University of Michigan - Ann Arbor MI
International Classification:

A61K 31/4025
C07D 207/09
A61K 31/40
A61P 25/16
A61P 25/00
A61K 48/00
A61P 7/06
A61P 35/00
A61P 13/12
A61P 9/10
A61P 31/00
A61K 38/43
C07D 405/10
A61P 3/10
US Classification:

424 941, 548526, 514422, 548569, 514428, 548568, 514 44 R
Abstract:

Glucosylceramide synthase inhibitors and compositions containing the same are disclosed. Methods of using the glucosylceramide synthase inhibitors in the treatment of diseases and conditions wherein inhibition of glucosylceramide synthase provides a benefit, like Gaucher disease and Fabry disease, also are disclosed.

Glucosylceramide Synthase Inhibitors And Therapeutic Methods Using The Same
view source
US Patent:

20180022697, Jan 25, 2018
Filed:

Feb 1, 2016
Appl. No.:

15/546320
Inventors:

- Ann Arbor MI, US
Akira Abe - Ann Arbor MI, US
Liming Shu - Ann Arbor MI, US
Michael William Wilson - Ann Arbor MI, US
Richard F. Keep - Ann Arbor MI, US
Duxin Sun - Ann Arbor MI, US
James A. Shayman - Ann Arbor MI, US
International Classification:

C07D 207/06
C07D 263/20
C07D 207/10
C07D 295/13
C07D 205/04
Abstract:

Glucosylceramide synthase inhibitors and compositions containing the same are disclosed. Methods of using the glucosylceramide synthase inhibitors in the treatment of diseases and conditions wherein inhibition of glucosylceramide synthase provides a benefit, like Gaucher disease and Fabry disease, also are disclosed.

Lysosomal Phospholipase A2 (Lpla2) Activity As A Diagnostic And Therapeutic Target For Identifying And Treating Systemic Lupus Erythematosus
view source
US Patent:

20160317626, Nov 3, 2016
Filed:

Apr 11, 2016
Appl. No.:

15/095685
Inventors:

- Ann Arbor MI, US
Akira Abe - Ann Arbor MI, US
Robert Kelly - Trenton MI, US
Jessica Kollmeyer - Ypsilanti MI, US
Ye Lu - Ann Arbor MI, US
International Classification:

A61K 38/45
G01N 33/68
Abstract:

The present invention is directed to methods for diagnosis and treatment of systemic lupus erythematosus and drug-induced systemic lupus erythematosus. More specifically, the specification describes methods using a lysosomal phospholipase A2 in methods for the diagnosis and treatment of autoimmune disorders such as systemic lupus erythematosus and drug-induced systemic lupus erythematosus.